Related Experiment Video
Updated: Jun 13, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
The Discovery of C7-Substituted Norbornyl Bisamides as RXFP1 Small Molecule Agonists
Shun Su1, Michael C Myers1, Donna M Bilder1
1Research and Development, Bristol Myers Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Researchers discovered a new compound, 39, that acts as a potent agonist for the relaxin receptor RXFP1. This compound shows promise for treating cardiovascular conditions like heart failure by mimicking relaxin
Area of Science:
- Pharmacology
- Cardiovascular Science
- Endocrinology
Background:
- Human relaxin-2 (relaxin) and its receptor RXFP1 are key regulators of cardiovascular function.
- RXFP1 agonism is a potential therapeutic strategy for heart failure.
- Previous research explored anthranilamide derivatives for RXFP1 modulation.
Purpose of the Study:
- To discover novel RXFP1 agonists with improved activity.
- To evaluate the potential of new compounds for cardiovascular therapeutics.
Main Methods:
- Chemical space exploration around anthranilamide 2.
- In vivo studies in rats to assess hemodynamic effects (heart rate).
- MicroCT imaging in mice to measure interpubic ligament (IPL) expansion.
Main Results:
- Discovery of lead compound 39 with enhanced human and rodent RXFP1 agonist activity.
- Compound 39 demonstrated dose-dependent heart rate increase in rats, mirroring relaxin's effects.
- Compound 39 induced significant IPL expansion in mice, a known relaxin-mediated response.
Conclusions:
- Compound 39 is a potent RXFP1 agonist with promising therapeutic potential for heart failure.
- The compound effectively recapitulates key in vivo relaxin activities.
- Further development of compound 39 is warranted for cardiovascular applications.
More Related Videos
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
09:09Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
Published on: September 20, 2016
Related Concept Videos
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Nucleophilic Aromatic Substitution: Addition–Elimination (SNAr)
The reaction begins with an attack of the nucleophile on the carbon that holds the leaving group. This results in the delocalization of the π electrons over the ring carbons. The resonance interaction between...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...